References [1] National Library of Medicine, Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts, Chang, C., Tsai, W, Hsu, Y, Pang, J.S., 2014 [2] National Library of Medicine, Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review, Vasireddi, N., Hahamyan, H., Salata, M., Karns, M., Calcei, J., Voos, J., Apostolakos, J., July 2025 [3] National Library of Medicine, Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts, Chang, C., Tsai, W., Hsu, Y., Pang, JS., November 2014
That is a meaningful difference in precision, especially when you are still getting used to drawing doses
Rigorous human studies are required to determine safety parameters, mechanistic specificity, and potential translational relevance before any clinical applications can be considered
We ship from U.S
This stability is unusual among peptide research compounds and allows investigators to use BPC-157 in both oral and parenteral administration designs in pre-clinical models
28 days from that first puncture, whether the vial sits at room temperature or in the fridge, and regardless of how much liquid remains